1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Spinal Muscular Atrophy Type II: new trials by email Literature Review of Spinal Muscular Atrophy Type II trials Research Report on Spinal Muscular Atrophy Type II
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi Onasemnogene Abeparvovec-xioi - Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II | Phase 3 | Active not recruiting | Novartis Gene Therapies | 85 | 2020-02-10 | 2026-09-24 |
Spinal Muscular Atrophies of Childhood (1)
Central Nervous System Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Heredodegenerative Disorders, Nervous System (1) · Motor Neuron Disease (1) · Muscular Atrophy, Spinal (1) · Nervous System Diseases (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1) · Spinal Cord Diseases (1)
Zolgensma (1)
Australia (1) · Belgium (1) · Canada (1) · France (1) · Italy (1) · Japan (1) · Taiwan (1) · United Kingdom (1) · United States (1)
Sitra Tauscher-Wisniewski, MD (1)
2019 (1)